

Dicerna Pharmaceuticals Inc  
Form 8-K  
February 18, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): February 11, 2014**

**DICERNA PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-36281**  
**(Commission**

**File Number)**  
**480 Arsenal Street**

**20-5993609**  
**(I.R.S. Employer**

**Identification Number)**

Edgar Filing: Dicerna Pharmaceuticals Inc - Form 8-K

**Building 1, Suite 120**

**Watertown, Massachusetts 02472**

**(Address of principal executive offices, including Zip Code)**

**Registrant's telephone number, including area code: (617) 621-8097**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2 below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4c)

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(e) *Compensatory Arrangements of Certain Officers.*

(f) *Disclosure of Bonuses and Total Compensation of Certain Officers.*

On February 11, 2014, the compensation committee of the board of directors of Dicerna Pharmaceuticals, Inc., a Delaware corporation (the Company), approved cash incentive awards for 2013 for the Company's named executive officers in the amounts reported in the Non-Equity Incentive Plan Compensation column for 2013 in the table below. In accordance with rules of the Securities and Exchange Commission (the SEC), the table below updates the Summary Compensation Table Year Ended December 31, 2013, which appears in the Company's registration statement on Form S-1 initially filed with the SEC on December 30, 2013, as subsequently amended and declared effective by the SEC on January 29, 2014 (the Registration Statement), to include the 2013 bonus information.

**Summary Compensation Table**

The following table provides a summary of compensation paid to our principal executive officer and our two other most highly compensated executive officers for the year ended December 31, 2013 (collectively, the named executive officers).

**Summary Compensation Table Year Ended December 31, 2013**

NAME AND PRINCIPAL POSITION	FISCAL YEAR	BASE SALARY (\$)	BONUS (\$) <sup>(2)</sup>	NON-EQUITY INCENTIVE PLAN <sup>(1)</sup>			ALL OTHER COMPENSATION (\$) <sup>(3)</sup>	TOTAL (\$)
				STOCK AWARDS (\$)	OPTION AWARDS (\$) <sup>(1)</sup>	COMPENSATION (\$) <sup>(2)</sup>		
Douglas M. Fambrough, III, Ph.D.	2013	375,000			1,151,485	164,063	8,875	1,699,423
Chief Executive Officer	2012	375,000				65,625	8,688	449,313
James E. Dentzer <sup>(4)</sup>	2013	20,401	45,000		882,813	9,235		957,449
Chief Financial Officer								
Bob D. Brown, Ph.D.	2013	315,000			445,778	118,125	78,654	957,557
Chief Scientific Officer, Senior Vice President	2012	315,000				47,250	73,108	435,358
James B. Weissman	2013	295,000			307,249	110,625	11,698	724,572
Chief Business Officer	2012	295,000			78,325	44,250	121,476	539,051

(1)

## Edgar Filing: Dicerna Pharmaceuticals Inc - Form 8-K

Pursuant to applicable SEC rules, the amounts reported in the Option Awards column of the table above reflect the fair value on the grant date of the option awards granted to our named executive officers during 2013 and 2012, and do not reflect the actual amounts earned. These amounts also include an incremental charge for the repricing of certain stock options held by Dr. Fambrough, Dr. Brown and Mr. Weissman during 2013. These values have been determined under the principles used to calculate the value of equity awards for purposes of our financial statements. For a discussion of the assumptions and methodologies used to calculate the amounts referred to above, please see the discussion of option awards contained in Note 10, Common Stock and Stock Option Plan, to our financial statements for the year ended December 31, 2012 and for the nine months ended September 30, 2013 included in the Registration Statement.

The amounts reported in this column for each executive for 2013 include certain grants of stock options that are subject to performance-based vesting requirements as described in the footnotes to the Outstanding Equity Awards at December 31, 2013 table below. These amounts are reported based on the probable outcome (as of the grant date) of the performance-based conditions applicable to the awards, as determined under generally accepted accounting principles. In each case, the amount was determined assuming that the maximum level of performance applicable to the award would be achieved.

- (2) These amounts include payments under our annual incentive bonus plan, which is based on our performance against certain operational and financial goals established by our compensation committee. Based on our overall performance against the performance objectives, our named executive officers were awarded bonuses of 125 percent of their target bonus levels for 2013 (with Mr. Dentzer's bonus being prorated to reflect his period of service with the Company during 2013) and were awarded bonuses of 50 percent of their target bonus levels for 2012. The amount reported in the Bonus column for Mr. Dentzer represents the first installment of a \$90,000 signing bonus provided under his employment agreement.
- (3) The amounts reported in this column consist of matching contributions we made to each executive's account under our 401(k) plan, as well as, in the case of Dr. Brown and Mr. Weissman, payment by us of certain temporary housing and relocation expenses and reimbursement for taxes incurred in connection with such payments.
- (4) Mr. Dentzer commenced employment with us in December 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 18, 2014

**DICERNA PHARMACEUTICALS, INC.**

By: /s/ James E. Dentzer  
James E. Dentzer  
Chief Financial Officer